Huiyu Pharmaceutical (688553.SH): Paclitaxel for injection (albumin binding type) obtained overseas marketing license

Zhitong Finance App News, Huiyu Pharmaceutical (688553.SH) issued an announcement. The company's subsidiary Seacross (Europe) Pharma Ltd. recently received marketing licenses for the company's injectable paclitaxel (albumin binding type) approved and issued by the Italian Medicines Administration and the Norwegian Medicines Administration, respectively.

The injectable paclitaxel (albumin binding type) developed by the company has obtained marketing licenses from Italy and Norway respectively, which helps the company to enrich its product pipeline in the international market, enhance the market's brand image, continue to expand the breadth and depth of international business, and further solidify the foundation for the sustainable development of the international market.